Pelthos Therapeutics Ord Shs
PTHS26.015USD
+3.345+14.76%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
80.41MMarket Cap
LossP/E TTM
More Details of Company
Pelthos Therapeutics Ord Shs Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Pelthos Therapeutics Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Richard Malamut
Dr. Richard Malamut
Independent Director
Independent Director
5.89K
+13600.00%
Mr. Richard Baxter
Mr. Richard Baxter
Independent Director
Independent Director
--
--
Mr. Ezra M. Friedberg
Mr. Ezra M. Friedberg
Independent Director
Independent Director
--
-100.00%
Mr. Scott Plesha
Mr. Scott Plesha
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Greenleaf
Mr. Peter Greenleaf
Chairman of the Board
Chairman of the Board
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Sai Rangarao
Mr. Sai Rangarao
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Matthew Pauls
Mr. Matthew Pauls
Independent Director
Independent Director
--
--
Mr. Francis P. (Frank) Knuettel, II
Mr. Francis P. (Frank) Knuettel, II
Chief Financial Officer, Treasurer, Company Secretary
Chief Financial Officer, Treasurer, Company Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Richard Malamut
Dr. Richard Malamut
Independent Director
Independent Director
5.89K
+13600.00%
Mr. Richard Baxter
Mr. Richard Baxter
Independent Director
Independent Director
--
--
Mr. Ezra M. Friedberg
Mr. Ezra M. Friedberg
Independent Director
Independent Director
--
-100.00%
Mr. Scott Plesha
Mr. Scott Plesha
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Greenleaf
Mr. Peter Greenleaf
Chairman of the Board
Chairman of the Board
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ligand Pharmaceuticals Inc
48.60%
3I Management LLC
9.72%
Murchinson Ltd.
9.07%
Balmoral Financial Group LLC
2.98%
The Vanguard Group, Inc.
2.17%
Other
27.47%
Shareholders
Shareholders
Proportion
Ligand Pharmaceuticals Inc
48.60%
3I Management LLC
9.72%
Murchinson Ltd.
9.07%
Balmoral Financial Group LLC
2.98%
The Vanguard Group, Inc.
2.17%
Other
27.47%
Shareholder Types
Shareholders
Proportion
Corporation
52.87%
Investment Advisor/Hedge Fund
19.81%
Hedge Fund
2.67%
Investment Advisor
2.23%
Individual Investor
1.04%
Other
21.37%
Institutional Shareholding
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
23
762.76K
24.71%
+416.33K
2025Q3
23
762.76K
24.89%
+686.23K
2025Q2
15
44.89K
7.45%
-74.71K
2025Q1
14
89.69K
14.94%
-16.15K
2024Q4
11
77.19K
12.98%
+14.42K
2024Q3
10
38.99K
6.70%
-15.38K
2024Q2
7
54.38K
9.43%
+29.19K
2024Q1
2
57.07K
9.90%
+57.07K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ligand Pharmaceuticals Inc
1.50M
49.51%
+1.50M
--
Jul 02, 2025
3I Management LLC
300.00K
9.9%
+269.90K
+896.68%
Jul 02, 2025
Murchinson Ltd.
280.00K
9.07%
+280.00K
--
Sep 30, 2025
Balmoral Financial Group LLC
92.07K
3.04%
+40.00K
+76.82%
Jul 02, 2025
The Vanguard Group, Inc.
66.84K
2.17%
+64.39K
+2634.70%
Sep 30, 2025
Ikarian Capital LLC
62.45K
2.02%
+62.45K
--
Sep 30, 2025
Key Recovery Group LLC
40.00K
1.32%
+40.00K
--
Jul 02, 2025
Knuettel (Francis P II)
11.10K
1.82%
-1.72K
-13.42%
Mar 21, 2025
Boothbay Fund Management, LLC
21.25K
0.69%
+21.25K
--
Sep 30, 2025
Diadema Partners LP
10.50K
0.34%
+10.50K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 27, 2025
Merger
10→1
Date
Type
Ratio
Jun 27, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Pelthos Therapeutics Ord Shs?
The top five shareholders of Pelthos Therapeutics Ord Shs are:
Ligand Pharmaceuticals Inc holds 1.50M shares, accounting for 49.51% of the total shares.
3I Management LLC holds 300.00K shares, accounting for 9.90% of the total shares.
Murchinson Ltd. holds 280.00K shares, accounting for 9.07% of the total shares.
Balmoral Financial Group LLC holds 92.07K shares, accounting for 3.04% of the total shares.
The Vanguard Group, Inc. holds 66.84K shares, accounting for 2.17% of the total shares.
Ligand Pharmaceuticals Inc holds 1.50M shares, accounting for 49.51% of the total shares.
3I Management LLC holds 300.00K shares, accounting for 9.90% of the total shares.
Murchinson Ltd. holds 280.00K shares, accounting for 9.07% of the total shares.
Balmoral Financial Group LLC holds 92.07K shares, accounting for 3.04% of the total shares.
The Vanguard Group, Inc. holds 66.84K shares, accounting for 2.17% of the total shares.
What are the top three shareholder types of Pelthos Therapeutics Ord Shs?
The top three shareholder types of Pelthos Therapeutics Ord Shs are:
Ligand Pharmaceuticals Inc
3I Management LLC
Murchinson Ltd.
Ligand Pharmaceuticals Inc
3I Management LLC
Murchinson Ltd.
How many institutions hold shares of Pelthos Therapeutics Ord Shs (PTHS)?
As of 2025Q4, 23 institutions hold shares of Pelthos Therapeutics Ord Shs, with a combined market value of approximately 762.76K, accounting for 24.71% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.18%.
What is the biggest source of revenue for Pelthos Therapeutics Ord Shs?
In --, the -- business generated the highest revenue for Pelthos Therapeutics Ord Shs, amounting to -- and accounting for --% of total revenue.
